header3_edited.jpg

Our Science: Overview

BOOSTING FSH POTENCY AND EFFICACY TO TRANSFORM INFERTILITY TREATMENT

Igyxos’ differentiated approach to infertility treatment is targeted at enhancing the activity of gonadotropins – hormones that are foundational for effective reproduction. We are developing a first-in-class mAb therapeutic, IGX12, that is designed to boost the bioactivity of Follicle Stimulating Hormone (FSH), a key hormone associated with the development of eggs in women and sperm in men. In men, FSH controls spermatogenesis. Inadequate levels of FSH create an absence of sperm production, resulting in infertility. In women, FSH controls folliculogenesis and the production of mature and fertilizable oocytes. Low levels of FSH can result in infertility as a consequence of the absence of ovulation. 

Igyxos is pioneering the development of novel therapeutics that identify monoclonal antibodies that significantly improve FSH receptor binding and activity.

CONFORMATIONAL MECHANISM OF ACTION 

Igyxos has validated our scientific approach through in vivo models, demonstrating that IGX12 has a mechanism of action (MOA) that binds to both α and β subunits of FSH and stabilizes the dimer. Binding to the FSH receptor facilitates the interaction of FSH with the receptor, resulting in increased activation by FSH. Based on pre-clinical data, we believe our mAb therapeutic approach has the potential for treating infertility in men and women with better effectiveness and supporting a simplified treatment regimen – alone or in combination with standard gonadotropin treatments.